Item 2.02 - Results of Operations and Financial Condition: The filing reports financial results and operational performance for Becton Dickinson & Co as of February 9, 2026 Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements and exhibits related to the reported results Company Information: Becton, Dickinson and Company, a New Jersey-incorporated surgical and…

Our analysis rates this filing BULLISH. BD's completion of the Waters Corporation combination represents a significant de-risking event that materially improves the company's risk profile. The removal of a major business segment (severity 8 risk) and shift to a more focused portfolio substantially…

Concern level: MODERATE (2.1/10). Key factors: Post-separation execution risk: 'New BD' must demonstrate sustainable profitability and growth in focused portfolio without the diversification of prior business mix; Transition complexity: Separation of major business segment (approximately one-third of prior revenue) creates near-term operational execution challenges; Market perception risk:…

Notable risk changes: Major de-risking event: Biosciences and Diagnostic Solutions business combination with Waters Corporation expected to close on filing date (February 9, 2026), eliminating approximately one-third of prior business and associated operational risks; Positive Q1 FY2026 performance: Revenue of $5.3B (+1.6% as reported, +0.4% FXN), adjusted diluted EPS of $2.91, and 'New BD' revenue growth of +2.5%…

The model predicts BDX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.